On January 5, 2022 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematological cancers reported that members of IMV’s executive management team will be presenting virtually at the Biotech ShowcaseTM 2022 investor conference which will be held January 10-12 and at the H.C. Wainwright Bioconnect 2022 conference held January 10-13 (Press release, IMV, JAN 5, 2022, View Source [SID1234598171]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A copy of IMV’s presentation for both of these events will be made available in the ‘Events, Webcasts & Presentations’ section of IMV’s website on the morning of January 10, 2022. Additionally, a webcast link to the H.C. Wainwright Bioconnect 2022 conference will also be available at 7:00 AM EST on January 10.